

TO BE COMPLETED BY THE PATIENT

To apply for assistance all information must be complete and include the following steps:

- Complete pages 1 and 2 and sign the Patient Declaration and Authorization to Share information on page 2
Ask your physician to complete pages 3-4 and sign page 4
Include a copy of your most recent 1040 or 1040EZ federal tax return

Fax to: 1-888-526-5168 or

Mail to: Johnson & Johnson Patient Assistance Foundation, Inc.

Patient Assistance Program

P.O. Box 221857, Charlotte, NC 28222-1857

If you have any questions, call 1-800-652-6227

1 Patient Information

Name: Telephone: Email:

Social Security #: Date of Birth: Gender: Male Female

Address (Street, City, State, ZIP):

2 Financial Information

Federal Taxes

A copy of my most recent 1040 or 1040EZ Federal tax return is attached.

I do not file federal taxes.

(Tax returns may be reviewed and additional documentation requested.)

Total Gross Yearly Income

Entire Household: \$

Household Size: The number of people who live in your home and are dependent on your household income:

3 Healthcare Insurance Information (Select all that apply.)

I do not have healthcare insurance

Private/HMO insurance

Insurance Company:

Policy ID #:

Group ID #:

Phone #:

Subscriber Name:

Date of Birth:

Relation to Patient:

Does the policy cover prescription drugs?

Yes

No

Unsure

Medicare insurance

Insurance Company:

Medicare Policy #:

Plan Name:

Are you enrolled in a Medicare prescription drug plan?

Yes No

Part D Policy #:

Part D Plan Name:

Phone #:

Medicaid insurance

Policy #:

Plan Name:

Phone #:

Other state/government insurance

Veterans Affairs (VA)

Policy #:

Plan Name:

My application is pending

Phone #:

ADAP AIDS Drug Assisted Program

Policy #:

Plan Name:

My application is pending

I am on a waiting list

SPAP State Patient Assistance Program

Policy #:

Plan Name:

My application is pending

Other:

Policy #:

Plan Name:

My application is pending

Phone #:

TO BE COMPLETED BY THE PATIENT: Patient should keep a copy of this page

4 Patient Declaration

I promise:

- The information on this form is correct and complete including all copies of documents proving my income.
The product(s) provided under this patient assistance program will not be sold or traded.
I will notify the Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) Patient Assistance Program within thirty (30) days if there is any change in the status of my eligibility (related to changes in income or health coverage) to receive products through this program.

Patient Authorization To Share Health Information: I allow my doctor(s), any health care providers, and my health plan or insurers to give medical information related to my use or need for products provided under the JJPAF Patient Assistance Program:

I understand:

- This information can include spoken or written facts about my health and payment benefits.
It can include copies of my health records.
People who work for JJPAF or the Program Administrator may see my information but they may use it only to help me get assistance with the costs of my drugs and to run the Program.
Every effort will be made to keep my information private but if it is accidentally given out, federal privacy laws will not protect it.

I know that I may refuse to sign this form. My choice about whether to sign this form will not change the way health care providers or insurers treat me. If I refuse to sign this form, I know that this means that I may no longer be able to receive assistance from the Program.

Patient Name (print): Patient Signature: Date

If applicable, your representative or Power of Attorney must sign below.

Patient Representative Name: Signature: Date

Contact information:

Relationship to patient and authority to make medical decisions for patient:

Power of Attorney Name: Signature: Date

Contact information:

We will contact you if additional documentation is required.

5 If applicable: Patient Authorization to Elect Representative for Purposes of Program Enrollment

I permit the Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) to speak with the following person about my application. This includes discussing the status of my application, insurance and financial questions, any missing documentation and other issues related to my application.

Name of Authorized Representative: Organization Name:

Telephone: Email:

By signing below, I am allowing this representative to speak on my behalf on any matter regarding my application with JJPAF.

Patient Signature: Date

TO BE COMPLETED BY THE PHYSICIAN

1 Products to be distributed (Select all that apply). This program is limited to patients being treated on an outpatient basis.

Patient Name: _____		Pharmacy Card Pharmacy pick up. Physician must provide a prescription.	Direct to Physician Shipped to the physician's office.	Direct to Patient Shipped to the patient's residence.
AXERT® (almotriptan malate)	Tablets	<input type="checkbox"/>	N/A	N/A
CONCERTA®† (methylphenidate HCl)	Extended-release tablets CII	<input type="checkbox"/>	N/A	N/A
DITROPAN® XL (oxybutynin chloride)	Extended-release tablets	<input type="checkbox"/>	N/A	N/A
DOXIL®† (doxorubicin HCl liposome)	Intravenous infusion	N/A	<input type="checkbox"/>	N/A
DURAGESIC®† (fentanyl)	Transdermal system CII	<input type="checkbox"/>	N/A	N/A
EDURANT® (rilpivirine)	Tablets	<input type="checkbox"/>	<input type="checkbox"/>	N/A
ELMIRON® (pentosan polysulfate sodium)	Capsules	<input type="checkbox"/>	N/A	N/A
HALDOL®† (haloperidol)	Injection for immediate-release	N/A	<input type="checkbox"/>	N/A
HALDOL®† Decanoate (haloperidol)	Injection for extended-duration for effect	N/A	<input type="checkbox"/>	N/A
IMBRUVICA® (ibrutinib)	Capsules	N/A	N/A	<input type="checkbox"/>
INTELENCE® (etravirine)	Tablets	<input type="checkbox"/>	<input type="checkbox"/>	N/A
INVEGA®† (paliperidone)	Extended-release tablets	<input type="checkbox"/>	<input type="checkbox"/>	N/A
INVEGA SUSTENNA®† (paliperidone palmitate)	Extended-release injectable suspension	N/A	<input type="checkbox"/>	N/A
INVEGA TRINZA™† (paliperidone palmitate)	Extended-release injectable suspension	N/A	<input type="checkbox"/>	N/A
INVOKAMET® (canagliflozin + metformin)	Tablets	<input type="checkbox"/>	N/A	N/A
INVOKANA® (canagliflozin)	Tablets	<input type="checkbox"/>	N/A	N/A
LEVAQUIN®† (levofloxacin)	<input type="checkbox"/> Tablets or <input type="checkbox"/> Oral solution	<input type="checkbox"/>	N/A	N/A
MONOVISC® (high molecular weight hyaluronan)	Injection	N/A	<input type="checkbox"/>	N/A
NATRECOR® (nesiritide)	Intravenous infusion	N/A	<input type="checkbox"/>	N/A
NUCYNTA® (tapentadol)	Immediate-release tablets CII	<input type="checkbox"/>	N/A	N/A
NUCYNTA® ER† (tapentadol)	Extended-release oral tablets CII	<input type="checkbox"/>	N/A	N/A
OLYSIO® (simeprevir)	Capsules	<input type="checkbox"/>	N/A	N/A
ORTHOVISC® (high molecular weight hyaluronan)	Injection	N/A	<input type="checkbox"/>	N/A
PANCREAZE® (pancrelipase)	Delayed-release capsules	<input type="checkbox"/>	<input type="checkbox"/>	N/A
PARAFON FORTE® DSC (chlorzoxazone)	Caplets	N/A	<input type="checkbox"/>	N/A
PREZCOBIX™ (darunavir 800mg/cobicistat 150mg)	Tablets	<input type="checkbox"/>	<input type="checkbox"/>	N/A
PREZISTA® (darunavir)	Tablets	<input type="checkbox"/>	N/A	N/A
PREZISTA® (darunavir)	Injection	<input type="checkbox"/>	<input type="checkbox"/>	N/A
PROCRIT®† (epoetin alfa)	Injection	<input type="checkbox"/>	<input type="checkbox"/>	N/A
Required: Is the patient being treated on renal dialysis? <input type="checkbox"/> Yes* <input type="checkbox"/> No				
RAZADYNE® (galantamine HBr)	<input type="checkbox"/> Tablets or <input type="checkbox"/> Oral solution	<input type="checkbox"/>	N/A	N/A
RAZADYNE® ER (galantamine HBr)	Extended-release capsules	<input type="checkbox"/>	N/A	N/A
REMICADE®† (infliximab)	Intravenous Infusion	N/A	<input type="checkbox"/>	N/A
RISPERDAL®† (risperidone)	<input type="checkbox"/> Tablets or <input type="checkbox"/> Oral solution	<input type="checkbox"/>	<input type="checkbox"/>	N/A
RISPERDAL CONSTA®† (risperidone)	Long-acting injection	N/A	<input type="checkbox"/>	N/A
RISPERDAL® M-TAB®† (risperidone)	Orally disintegrating tablets	<input type="checkbox"/>	<input type="checkbox"/>	N/A
SIMPONI®† (golimumab)	<input type="checkbox"/> SmartJect® or <input type="checkbox"/> prefilled syringe	<input type="checkbox"/>	N/A	N/A
SIMPONI ARIA®† (golimumab)	Intravenous Infusion	N/A	<input type="checkbox"/>	N/A
SPORANOX®† (itraconazole)	Capsules	<input type="checkbox"/>	N/A	N/A
SPORANOX®† (itraconazole)	Oral solution	N/A	<input type="checkbox"/>	N/A
STELARA® (ustekinumab)	Injection	<input type="checkbox"/>	<input type="checkbox"/>	N/A
SYLVANT® (siltuximab)	Intravenous Infusion	N/A	<input type="checkbox"/>	N/A
TERAZOL® 3 (terconazole)	Cream	N/A	<input type="checkbox"/>	N/A
TERAZOL® 7 (terconazole)	Cream	N/A	<input type="checkbox"/>	N/A
TOPAMAX® (topiramate)	<input type="checkbox"/> Tablets or <input type="checkbox"/> Sprinkle capsules	<input type="checkbox"/>	N/A	N/A
ULTRACET®† (tramadol HCl/acetaminophen)	Tablets CIV	<input type="checkbox"/>	N/A	N/A
ULTRAM® (tramadol HCl)	Tablets CIV	<input type="checkbox"/>	N/A	N/A
ULTRAM® ER (tramadol HCl)	Extended-release tablets CIV	<input type="checkbox"/>	N/A	N/A
XARELTO®† (rivaroxaban)	Tablets	<input type="checkbox"/>	N/A	N/A
ZYTIGA® (abiraterone acetate)	Tablets	<input type="checkbox"/>	N/A	N/A

*Contact Amgen Inc. 1-800-772-6436. † See full U.S. prescribing information, including Black Box warning. Revised: August 2015